Iovance Biotherapeutics - The Navy Yard Production Facility
Courtesy of DIGSAU.
Philadelphia
Iovance Biotherapeutics entered into a lease agreement in May of 2019 to construct a 136,000-sf facility at the Philadelphia Navy Yard. Featuring modular processes for optimal scalability, the building will support commercial and clinical production of therapeutics based on tumor-infiltrating lymphocyte (TIL) technologies. The $125 million facility is slated for completion in mid-2021. Iovance will contribute approximately $75 million towards the cost of the building over three years for equipment and construction of the manufacturing suites. The project team includes Gattuso Development Partners, architectural consultant DIGSAU, designer and construction manager CRB, and lease advisor JLL.
| Organization | Project Role |
|---|---|
|
CRB
|
Designer and Construction Manager
|
|
JLL
|
Lease Advisor
|
Source
